地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771149750
传真:18995651644
邮箱:sales@amyjet.com

PhytoTechnology(简称PhytoTech)公司是一家专门从事于研发和生产植物组织培养基,植物学技术相关产品的一家科研生产性企业。由Dr. Kenneth C. Torres博士和他的妻子Janet 于1997年在美国Lenexa, Kansas州创立,随着公司产品的不断改进和更新,目前PhytoTech公司已经成为了世界上著名的植物生物学类产品的生厂商和原料供应商,其公司产品以稳定的质量和优质的价格已赢得了世界范围内众多客户的认可,并在植物学的各个领域内广泛使用。
PhytoTechnology Laboratories manufactures and distributes products to the plant tissue culture, plant biotechnology, and plant science markets. Our products are used to mass propagate plants on sterile culture media in laboratory settings. We also supply products for the genetic improvement of plants through gene transformation research. Manufacturing, product development, administration and distribution of products are all performed at the PhytoTechnology Laboratories campus (20,000 square feet of production and research and development space) in Overland Park, a suburb of the Kansas City metro area in Kansas. This central US location provides direct access to most major markets around the world.
PhytoTechnology公司主要产品包括:
Plant Media
Biochemicals
Molecular Biology
Microbiology
Phytopathology
Phycology
Seed Testing
Kits Equipment
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

E&K Scientific公司成立于1975年,是生物技术和制药研究实验室提供实验试剂和仪器设备的主要供应商,有着超过40年的经验。
At E&K Scientific our mission is to excel in the distribution of life science research supplies by offering an unparalleled customer experience centered on technical expertise, innovation, and personalized service.
E&K offers almost 50 years of experience as a premier provider of laboratory supplies and instrumentation to the Academic, Biotech, and Pharmaceutical Research Laboratories. The company was founded in 1975 by Egon and Kay Ruf and their son, Brian Ruf, took over as President and CEO in 2000.
E&K Scientific公司的主要产品包括:
Biological Buffers
Blotting & Electrophoresis
Cell Culture
Chromatography Supplies
DNA/RNA Purification
Equipment & Instruments
Filtration & Separation
Gloves & Apparel
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://applied.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="E&K Scientific"> E&K Scientific
艾美捷科技特约代理Exalpha公司产品。Exalpha位于美国迈阿密,成立20余年来,坚持以切实解决客户需求为导向,提供高品质的产品。
Exalpha was founded over 20 years ago by a group of scientists dedicated to accelerating the pace of discovery in the life science arena by rapidly developing and marketing unique products at the forefront of science.
In order to develop great products, you have to ask the right questions when you start. Where some companies are satisfied with ‘average’, ‘good enough’ or ‘me too’ products, Exalpha only settles for products that answer the pertinent questions. Exalpha continually monitors scientific trends and recent literature, we strive to produce products that answer real needs. Exalpha has a long history of developing uniquely superior products that simply perform well, allowing researchers to focus on the task at hand and not on the quality of a supplier’s products.
产品主要包括:
Buffers and Reagents
Control Antibodies
Control Lysates
Kits
Proteins and Peptides
Primary Antibodies
Secondary Antibodies
Serum
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://applied.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Exalpha"> Exalpha

艾美捷科技代理Advansta全系列Western Blot试剂及分子生物学试剂。
Advansta成立于2005年,位于美国加州Menlo Park,主要研发和生产蛋白定性&定量试剂,这些产品在实验中表现优异、操作简单便捷。产品主要包括荧光Western Blot试剂、化学发光Western Blot试剂、ELISA试剂盒、电泳试剂、抗体及抗体标记产品、样品制备试剂、蛋白纯化试剂、蛋白染色试剂、缓冲液及蛋白鉴定服务等。
Founded in 2005 and headquartered in Menlo Park, California, Advansta accelerates life science research by developing and supplying novel protein characterization tools that offer superior performance, simplicity,and convenience. With over 200 citations in 2014 alone, our flagship products have become recognized as the most sensitive chemiluminescent substrates on the market.
产品包括:
Fluorescent Western blotting
Chemiluminescent Western blotting
ELISA
Electrophoresis
Antibodies and antibody labeling
Sample preparation
Purification
Protein staining
Buffers and solutions
Custom services
" data-original="http://applied.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Advansta"> Advansta
艾美捷科技代理StressMarq品牌。
StressMarq公司为生命科学和药物发现/生物制药市场生产高质量、尖端的研究产品。StressMarq公司产品包括:用于神经退行性疾病研究的原纤维、寡聚体和单体蛋白质制剂,包括α突触
核蛋白、tau蛋白、β淀粉样蛋白、SOD1蛋白和TTR蛋白等。StressMarq的战略重点是协助研究人员研究阿尔茨海默氏症、帕金森氏症和其他神经退行性疾病。除了专注于神经退行性疾病研
究的蛋白质外,StressMarq公司多样化的产品组合抗体、试剂盒、小分子和其他蛋白质,也广泛应用于神经科学、癌症研究和细胞信号传导等一系列生命科学领域。产品包括:
(1)抗体:提供数百种经过高度验证的单克隆和多克隆抗体.
(2)抗体偶联物:从一系列荧光团、蛋白质或酶偶联物中进行选择。
(3)检测试剂盒:浏览我们精选的细胞信号传导、细胞和氧化应激研究试剂盒。
(4)蛋白质:专门研究α突触核蛋白、tau和淀粉样蛋白β的纤维形式、寡聚形式和单体。
(5)小分子:抑制剂、拮抗剂、激动剂、激活剂和配体。
< " data-original="http://applied.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理StressMarq品牌"> 艾美捷科技代理StressMarq品牌
DiaMetra公司位于意大利Perugia,致力于为诊断行业提供高品质产品,包括标品和检测试剂盒,涉及的检测领域包括:唾液试剂盒、高血压及钙的代谢、自体免疫疾病、糖尿病指标检测、肿瘤标志物、固醇类激素、性激素、甲状腺激素检测等。
Diametra is dedicated to providing quality products and the highest level of service in its target diagnostics segments. Through innovation and total commitment we strive to create value for our people, our customers and for the shareholders.
As an organization we constantly strive for innovation, not simply in the products we bring to the market but also in the way we interact with our customers and with each other. This is grounded in our solution driven approach to partnership.
产品主要应用领域:
Saliva kits
Hypertension / Calcium Metabolism
Controls
Autoimmune Diseases
Diabetes Monitoring
Tumor Markers
Steroids Hormones
Fertility Proteic Hormones
Thyroid Monitoring
Circulating Immuno Complexes
Miscellaneous
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

艾美捷科技特约代理Enzyme Research Laboratories公司产品。
Enzyme Research Laboratories公司在过去的30年中已生产和销售多种用于基础研究的凝血酶和辅因子。通过不断追求最优质的产品,赢得了信任,Enzyme Research Laboratories通过提供单克隆抗体和多克隆抗体服务于科学研究和临床诊断领域。
For over 30 years Enzyme Research Laboratories has been manufacturing and distributing a variety of enzymes and cofactors used in basic coagulation research. By constantly striving for products of utmost quality, ERL has earned the trust of coagulation research communities worldwide. ERL is dedicated to serving the research and diagnostic communities by offering a complementary line of monoclonal and polyclonal antibodies.
Enzyme Research Laboratories公司的主要产品包括:
Monoclonal
Polyclonal
Paired Antibodies
Snake Venom Protein
PC Activator
Factor X Activator-RVV
Canine Proteins
Murine Proteins
Porcine Proteins
Rabbit Proteins
Rat Proteins
Des-Gla Proteins
按照研究领域细分:
Zymogens
Enzymes
CoFactors
Inhibitors
Human Fibrinogen
产品清单包括:
| Human Coagulation | |||
| 分类 | 产品清单 | 编号 | 规格 |
| Human Coagulation-Zymogens | Human Prothrombin | HP 1002 | 9.0 mg, 90 mg |
| Human Factor VII | HFVII 1007 | 0.1 mg, 1.0 mg | |
| Human Protein C | HPC 1001 | 0.1 mg, 1.0 mg | |
| Human Factor IX | HFIX 1009 | 0.5 mg | |
| Human Factor X | HFX 1010 | 0.8 mg | |
| Human Factor XI | HFXI 1111 | 0.1 mg, 1.0 mg | |
| Human Factor XIII | HFXIII 1313 | 0.25 mg, 1.0 mg | |
| Human Factor XII | HFXII 1212 | 0.5 mg, 1.0 mg | |
| Human Prekallikrein | HPK 1302 | 1.0 mg | |
| Sing. Chain High Molecular Wt. Kininogen | HK 1300 | 1.0 mg | |
| Two Chain High Molecular Wt. Kininogen | 2HK 1301 | 1.0 mg | |
| Human Glu-Plasminogen | HPg 2001 | 1.0 mg | |
| Human Lys-Plasminogen | LPg 2002 | 1.0 mg | |
| Human Coagulation-Enzymes | Human Alpha Thrombin | HT 1002a | 1000 units |
| Human Gamma Thrombin | HGT | 1.0 mg | |
| Human Factor VIIa | HFVIIa | 0.1 mg, 1.0 mg | |
| Human Activated Protein C | APC | 0.1 mg, 1.0 mg | |
| Human Factor IXa Beta | HFIXa 1080 | 0.5 mg | |
| Human Factor Xa | HFXa 1011 | 0.8 mg | |
| Human Factor XIa | HFXIa 1111a | 0.1 mg, 1.0 mg | |
| Human Factor Alpha-XIIa | HFXIIa 1212a | 0.5 mg, 1.0 mg | |
| Human Factor XIIa beta | HFXIIab | 0.1 mg, 1.0 mg | |
| Human Factor XIIIa | HFXIIIa 1314 | 0.25 mg, 1.0 mg | |
| Human Kallikrein | HPKa 1303 | 1.0 mg | |
| Human Plasmin | HPlasmin | 1.0 mg | |
| Human Coagulation-CoFactors | Human Protein S | HPS | 1.0 mg |
| Human Protein Z | HPZ | 0.5 mg | |
| Human Fibronectin | FN | 1.0 mg | |
| Human Coagulation-Inhibitors | Alpha2-Antiplasmin | α2AP | 0.1 mg, 1.0 mg |
| Corn Trypsin Inhibitor | CTI | 1.0 mg | |
| Human Antithrombin | HAT | 1.0 mg | |
| Human Coagulation-Platelets & Plasma Proteins | Human GPIIbIIIa | GP2b3a | 1.0 mg |
| Platelet Factor 4 | PF4 | 0.1 mg | |
| Apolipoprotein | HAPO-H | 0.1 mg | |
| Human Coagulation-Human Fibrinogen | Human Fibrinogen 1, 2, & 3 | FIB 1, FIB 2, FIB 3 | 1.0 gram |
| Peak 1 Fib (XIII free) | P1 FIB | 10.0 mg | |
| Peak 2 Fibrinogen | P2 FIB | 10 mg | |
<<
| Bovine Coagulation | |||
| 分类 | 产品清单 | 编号 | 规格 |
| Bovine Coagulation-Zymogens | Bovine Protein C | BPC 1003 | 1.0 mg |
| Bovine Prothrombin | BP 1004 | 10 mg | |
| Bovine Factor IX | BFIX 1005 | 0.5 mg | |
| Bovine Factor X | BFX 1006 | 1.0 mg | |
| Bovine Plasminogen | BPG | 1.0 mg | |
| Bovine Coagulation-Enzymes | Bovine Activated Protein C | BPCa | 0.1 mg |
| Bovine Alpha-Thrombin | BT 1002a | 1000 units | |
| Bovine Factor IXa Beta | BFIXa 1080 | 0.5 mg | |
| Bovine Factor Xa | BFXa | 1.0 mg | |
| Bovine Factor XIa | BFXIa 11a | 1.0 mg | |
| Bovine Coagulation-CoFactors | Bovine Factor V/Va | BFV/Va | 1.0 mg, 5.0 mg |
| Bovine Coagulation-Inhibitors | Bovine Antithrombin | BAT | 1.0 mg |
| Bovine Coagulation-Platelets & Plasma Proteins | Bovine Fibrinogen, Plasminogen Depleted | BFIB1 | 1.0 gram |
| Antibodies | |||
| 分类 | 产品清单 | 编号 | 规格 |
| Antibodies-Monoclonal | Anti-Human Factor V | Mab HFV | 0.1 mg , 0.5 mg |
| Anti-Human Factor VII | Mab HFVII | 0.1 mg , 0.5 mg | |
| Anti-Human Factor VIII | Mab HFVIII | 0.1 mg , 0.5 mg | |
| Anti-Human Factor VIII | Mab HFVIII-8001 | 0.1 mg , 0.5 mg | |
| Anti-Human Factor VIII | Mab HFVIII-8011 | 0.1 mg , 0.5 mg | |
| Anti-Human Factor VIII | Mab HFVIII-8002 | 0.1 mg , 0.5 mg | |
| Anti-Human Factor VIII | Mab HFVIII-8040 | 0.1 mg , 0.5 mg | |
| Anti-Human Factor IX | Mab HFIX | 0.1 mg , 0.5 mg | |
| Anti-Human Factor IX | Mab HFIX-102 | 0.1 mg , 0.5 mg | |
| Anti-Human Factor IX | Mab HFIX-001 | 0.1 mg , 0.5 mg | |
| Anti-Human Factor X | Mab HFX | 0.1 mg , 0.5 mg | |
| Anti-Human Factor X Light Chain | Mab HFX-LC | 0.1 mg , 0.5 mg | |
| Anti-Human Factor X Heavy Chain | Mab HFX-HC | 0.1 mg , 0.5 mg | |
| Anti-Human Factor XI | Mab HFXI | 0.1 mg , 0.5 mg | |
| Anti-Human Factor XII | Mab HFXII | 0.1 mg , 0.5 mg | |
| Anti-Human Factor XIII | Mab HFXIII | 0.1 mg , 0.5 mg | |
| Anti-Human Antithrombin | Mab HAT | 0.1 mg , 0.5 mg | |
| Anti-Thrombin | Mab IIa | 0.1 mg , 0.5 mg | |
| Anti-Human Prothrombin | Mab HFII | 0.1 mg , 0.5 mg | |
| Anti-Human Protein C | Mab HPC | 0.1 mg , 0.5 mg | |
| Anti-Human Tissue Factor | Mab TFE | 0.1 mg , 0.5 mg | |
| Anti-Human vWF | Mab VWF | 0.1 mg , 0.5 mg | |
| Anti-Human GPIIbIIIa | Mab GP2b3a | 0.1 mg , 0.5 mg | |
| Anti-Plasminogen | Mab HPG-030 | 0.1 mg , 0.5 mg | |
| Anti-Plasminogen | Mab HPG | 0.1 mg , 0.5 mg | |
| Anti-Vitronectin | Mab VN | 0.1 mg , 0.5 mg | |
| Anti-C4 Binding Protein | Mab C4BP | 0.1 mg , 0.5 mg | |
| Anti-PA Kringle 4 | Mab PA K4 | 0.1 mg , 0.5 mg | |
| Anti-PA Kringle 1-4 | Mab PA K1-4 | 0.1 mg , 0.5 mg | |
| Anti-PA Kringle 1-3 | Mab PA K1-3 | 0.1 mg , 0.5 mg | |
| Anti-Human Fibrinogen | Mab FIB | 0.1 mg , 0.5 mg | |
| Anti-Tissue Plasminogen Activator | Mab TPA | 0.1 mg , 0.5 mg | |
| Antibodies-Polyclonal | Sheep, purified IgG | SAFG-IG | 10 mg |
| Sheep, affinity purified, IgG | SAFG-AP | 0.5 mg | |
| Sheep, peroxidase conjugated. IgG | SAFG-HRP | 0.2 mg | |
| Sheep, affinity purified peroxidase conjugated 0.1 mg | SAFG-APHRP | 0.1 mg | |
| sheep, affinity purified IgG | *SARFG-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG | *SARFG-HRP | 0.2 mg | |
| Sheep, purified IgG | *SAFGP-IG | 5 mg | |
| Sheep, peroxidase conjugated IgG | *SAFGP-HRP | 0.2 mg | |
| Sheep, purified IgG | SAFNE-IG | 10 mg | |
| Sheep, peroxidase conjugated. IgG | *SAFNE-HRP | 0.2 mg | |
| sheep, purified IgG | *SAFPA-IG | 10 mg | |
| sheep, affinity purified IgG | *SAFPA-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG | *SAFPA-HRP | 0.2 mg | |
| sheep, purified IgG | SAFII-IG | 10 mg | |
| sheep, affinity purified IgG | SAFII-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG | SAFII -HRP | 0.2 mg | |
| sheep, Prothrombin Fragment-1, affinity purified IgG | SAFII-F1AP | 0.5 mg | |
| sheep, Prothrombin Fragment-2, affinity purified IgG | SAFII-F2AP | 0.5 mg | |
| sheep, purified IgG | SAHT-IG | 10 mg | |
| sheep, affinity purified IgG, (Prothrombin Adsorbed) | SAHT-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG | SAHT-HRP | 0.2 mg | |
| sheep, purified IgG | *SABT-IG | 10 mg | |
| sheep, affinity purified IgG | SABT-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG | *SABT-HRP | 0.2 mg | |
| sheep, purified IgG, 10 mg | *SART-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | *SART-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | *SART-HRP | 0.2 mg | |
| sheep, purified IgG, 10 mg | SAFV-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAFV-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAFV-HRP | 0.2 mg | |
| sheep, purified IgG, 10 mg | SAFVII-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAFVII-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAFVII-HRP | 0.2 mg | |
| sheep, affinity purified IgG Fluorescein Conjugate, 0.1 mg | *SAFVII-APFTC | 0.1 mg | |
| sheep, purified IgG, 10 mg | SAF8C-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAF8C-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAF8C-HRP | 0.2 mg | |
| sheep, affinity purified IgG Fluorescein Conjugate, 0.1 mg | *SAF8C-APFTC | 0.1 mg | |
| sheep, purified IgG, 5 mg | SAC8C-IG | 5mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | *SAC8C-HRP | 0.2 mg | |
| goat, purified IgG, 10 mg | GAFIX-IG | 10 mg | |
| goat, affinity purified IgG, 0.5 mg | GAFIX-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | GAFIX-HRP | 0.2 mg | |
| goat, peroxidase conjugated affinity purified IgG, 0.1 mg | GAFIX-APHRP | 0.1 mg | |
| goat, affinity purified IgG Fluorescein Conjugate, 0.1mg | *GAFIX-APFTC | 0.1 mg | |
| sheep, purified IgG, 10 mg | SAFIX-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAFIX-AP | 0.5 mg | |
| sheep, peroxidase conjugated affinity purified IgG, 0.1 mg | SAFIX-APHRP | 0.1 mg | |
| goat, purified IgG, 10 mg | GAFX-IG | 10 mg | |
| goat, affinity purified IgG, 0.5 mg | GAFX-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | GAFX-HRP | 0.2 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAFX-AP | 0.5 mg | |
| rabbit, peroxidase conjugated IgG, 0.2 mg | RAFX-HRP | 0.2 mg | |
| goat, purified IgG, 5 mg | GAFXI-IG | 5 mg | |
| goat, affinity purified IgG, 0.5 mg | GAFXI-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | GAFXI-HRP | 0.2 mg | |
| sheep, purified IgG, 5.0 mg | SAFXI-IG | 5.0 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAFXI-AP | 0.5 mg | |
| goat, purified IgG, 5 mg | GAFXII-IG | 5 mg | |
| goat, affinity purified IgG, 0.5 mg | GAFXII-AP | 0.5 mg | |
| goat peroxidase conjugated IgG, 0.2 mg | GAFXII-HRP | 0.2 mg | |
| sheep, purified IgG, 10 mg | SAFXIII-IG | 10 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAFXIII-HRP | 0.2 mg | |
| sheep, purified IgG, 10 mg | SAF13A-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAF13A-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | *SAF13A-HRP | 0.2 mg | |
| sheep, purified IgG, 10 mg | SAPK-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAPK-AP | 0.5 mg | |
| sheep, HRP-AP IgG, 0.1 mg | SAPK-APHRP | 0.1 mg | |
| goat, purified IgG, 5 mg | *GAPC-IG | 0.5 mg | |
| goat, affinity purified IgG, 0.5 mg | GAPC-AP | 0.5 mg | |
| sheep, purified IgG, 10 mg | SAPC-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAPC-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAPC-HRP | 0.2 mg | |
| goat, purified IgG, 5 mg | GAPS-IG | 5mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | GAPS-HRP | 0.2 mg | |
| sheep, purified IgG, 10 mg | SAPS-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAPS-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAPS-HRP | 0.2 mg | |
| goat, purified IgG, 5 mg | *GAPG-IG | 0.5 mg | |
| goat, affinity purified IgG, 0.5 mg | *GAPG-AP | 0.5 mg | |
| goat, peroxidase conjugated affinity purified IgG, 0.1 mg | GAPG-APHRP | 0.1mg | |
| sheep, purified IgG, 5 mg | *SAPG-IG | 5 mg | |
| sheep, affinity purified IgG, 0.5 mg | *SAPG-AP | 0.5 mg | |
| sheep, purified IgG, 10 mg | *SAPAI-IG | 10 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAPAI-HRP | 0.2mg | |
| sheep, affinity purified IgG, 0.5 mg | SATAFI-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SATAFI-HRP | 0.2mg | |
| sheep, purified IgG, 10 mg | *SATPA-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SATPA-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SATPA-HRP | 0.2mg | |
| sheep, purified IgG, 10 mg | *SAAT-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAAT-AP | 0.5 mg | |
| sheep, peroxidase conjugated affinity purified IgG, 0.1 mg | SAAT-APHRP | 0.1mg | |
| goat, purified IgG, 10 mg | *GAAT-IG | 10 mg | |
| goat, affinity purified IgG, 0.5 mg | GAAT-AP | 0.5 mg | |
| goat, purified IgG, 5 mg | *GAHC2-IG | 5 mg | |
| goat, affinity purified IgG, 0.5 mg | GAHC2-AP | 0.5 mg | |
| goat, peroxidase conjugated affinity purified IgG, 0.2 mg | *GAHC2-APHRP | 0.2mg | |
| goat, affinity purified IgG, 0.5 mg | *GAPCI-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | *GAPCI-HRP | 0.2mg | |
| goat, purified IgG, 5 mg | *GA2AP-IG | 5 mg | |
| goat, affinity purified IgG, 0.5 mg | GA2AP-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | GA2AP-HRP | 0.2mg | |
| sheep, purified IgG, 10 mg | SA2AP-IG | 10 mg | |
| sheep, purified IgG, 10 mg | *SA1AT-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | *SA1AT-AP | 0.5 mg | |
| sheep, peroxidase conjugated -affinity purified IgG, 0.1 mg | SA1AT-APHRP | 0.1mg | |
| goat, purified IgG, 10 mg | *GA1AT-IG | 10 mg | |
| goat, affinity purified IgG, 0.5 mg | GA1AT-AP | 0.5 mg | |
| goat, purified IgG, 10 mg | *GAA2M-IG | 10 mg | |
| goat, affinity purified IgG, 0.5 mg | GAA2M-AP | 0.5 mg | |
| goat, peroxidase conjugated-affinity purified IgG, 0.1 mg | *GAA2M-APHRP | 0.1mg | |
| sheep, purified IgG, 10 mg | *SAPF4-IG | 10 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SAPF4-HRP | 0.2mg | |
| goat, purified IgG, 5 mg | *GAB2G-IG | 5 mg | |
| goat, affinity purified IgG, 0.5 mg | GAB2G-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | GAB2G-HRP | 0.2mg | |
| goat, purified IgG, 2.5 mg | GAVWF-IG | 5 mg | |
| goat, affinity purified IgG, 0.5 mg | GAVWF-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.15 mg | GAVWF-HRP | 0.1mg | |
| sheep, purified IgG, 5 mg | SACWF-IG | 5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SACWF-HRP | 0.2mg | |
| sheep, purified IgG, 5 mg | SARTW-IG | 5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SARTW-HRP | 0.2mg | |
| sheep, purified IgG, 10 mg | SATF-IG | 10 mg | |
| sheep, peroxidase conjugated, 0.2 mg | *SATF-HRP | 0.2mg | |
| mouse, Fluorescein Conjugate, 0.1 mg | MATF-FITC | 0.1mg | |
| sheep, purified IgG, 10 mg | *SATFPI-IG | 10 mg | |
| sheep, purified IgG, 10 mg | *SAVN-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SAVN-AP | 0.5 mg | |
| sheep, peroxidase conjugated affinity purified, 0.1 mg | SAVN-APHRP | 0.1mg | |
| goat, purified IgG, 5 mg | GACINH-IG | 5 mg | |
| goat, affinity purified IgG, 0.5 mg | GACINH-AP | 0.5 mg | |
| goat, peroxidase conjugated IgG, 0.2 mg | GACINH-HRP | 0.2mg | |
| sheep, purified IgG, 10 mg | *SANE-IG | 10 mg | |
| sheep, affinity purified IgG, 0.5 mg | SANE-AP | 0.5 mg | |
| sheep, peroxidase conjugated IgG, 0.2 mg | SANE-HRP | 0.2mg | |
| sheep, purified IgG, 10 mg | SA2B3A-IG | 10 mg | |
| sheep, peroxidase conjugated affinity purified IgG, 0.5 mg | SAR-APHRP | 0.5 mg | |
| -Rabbit non-immune IgG, 10 mg | NIR-IG | 10 mg | |
| -Sheep non-immune IgG, 20 mg | NIS-IG | 20mg | |
| -Sheep non-immune FITC, 0.1 mg | *NIS-FITC | 0.1mg | |
| -Goat non-immune IgG, 10 mg | NIG-IG | 10 mg | |
| donkey, peroxidase conjugated affinity purified IgG, 0.5 mg | DAS-APHRP | 0.5 mg | |
| Antibodies-Paired Antibodies | von Willebrand Factor | VWF-EIA | - |
| Factor V | FV-EIA | - | |
| Factor VII | FVII-EIA | - | |
| Factor VIII:C | FVIII:C-EIA | - | |
| Factor IX | FIX-EIA | - | |
| Factor X | FX-EIA | - | |
| Factor XI | FXI-EIA | - | |
| Factor XII | FXII-EIA | - | |
| Factor XIII | FXIII-EIA | - | |
| Prothrombin | FII-EIA | - | |
| Protein S | PS-EIA | - | |
| Protein C | PC-EIA | - | |
| Alpha 1 Antitrypsin | A1AT-EIA | - | |
| Antithrombin III | ATIII-EIA | - | |
| Thrombin-Antithrombin Complex | TAT-EIA | - | |
| Plasminogen | PG-EIA | - | |
| Tissue Plasminogen Activator | TPA-EIA | - | |
| Fibrinogen | FG-EIA | - | |
| Apolipoprotein-H (B2-Glycoprotein) | APOH-EIA | - | |
| Canine Factor VIII | CFVIII-EIA | - | |
| Canine Factor IX | CFIX-EIA | - | |
| Prekallikrein | PK-EIA | - | |
| Substrates | |||
| 分类 | 产品清单 | 编号 | 规格 |
| Substrates-Substrates | PlasminChrom | 100-01 | 5mg |
| Substrates-Substrates | ThrombinChrom | 100-02 | 5mg |
| Substrates-Substrates | RGR-XaChrom | 100-03 | 5mg |
| Snake Venom Protein | |||
| 分类 | 产品清单 | 编号 | 规格 |
| Snake Venom Protein | Factor X Activator-RVV | RVV-X | 0.1 mg |
| Other Products | ||
| 分类 | 产品清单 | 编号 |
| Other Products-Canine Proteins | Canine Fibrinogen | CFib |
| Canine Thrombin | CIIa | |
| Canine Factor IX | CFIX | |
| Canine Factor X | CFX | |
| Canine Factor Xa | CFXa | |
| Other Products-Murine Proteins | Murine Fibrinogen | MFg |
| Murine Antithrombin III | MAT | |
| Murine Thrombin | MIIa | |
| Murine Factor XIII | MFXIII | |
| Murine Plasminogen | MPg | |
| Other Products-Porcine Proteins | Porcine Factor Xa | PFXa |
| Porcine Thrombin | PIIa | |
| Porcine Fibrinogen | PFib | |
| Other Products-Rabbit Proteins | Rabbit Fibrinogen | RbFg |
| Rabbit Factor Xa | RbXa | |
| Rabbit Factor X | RbX | |
| Rabbit Thrombin | RbIIa | |
| Other Products-Rat Proteins | Rat Fibrinogen | RFib |
| Rat Thrombin | RIIa | |
| Rat Factor Xa | RFXa | |
| Other Products-Des-Gla Proteins | Des-Gla-Human Protein C | HPC-GD |
| Des-Gla-Human Activated Protein C | APC-GD | |
| Des-Gla-Human Factor X | HFX-GD | |
| Des-Gla-Human Factor Xaβ | HFXab-GD | |
| Des-Gla-Human Factor VIIa | HFVIIaGD | |
| Des-Gla-Human Prothrombin | HP-GD | |
| Other Products-Inactivated Proteins | Human Thrombin | HTi |
| Human Factor VIIa | HFVIIai | |
| Human Factor IXaß | HFIXai | |
| Human Activated Protein C | APCi | |

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://applied.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
<艾美捷科技代理MicroFIT品牌全系列产品
MicroFIT是一家在生物/医疗领域具有显著影响力的企业,专注于基于模拟人体环境和组织的平台技术,致力于为生物医疗领域提供创新的产品和服务。公司以成为“基于Bio-Convergence技术的仿生平台领先企业”为目标,不断探索和研发,旨在成长为一家提供个性化医疗所需仿生平台的全球性公司。

▍MicroFIT产品线
● StemFIT 3D-Plastic系列
StemFIT 3D-Plastic系列产品采用PS(聚苯乙烯)材料设计,融合了多种实用功能,旨在使大规模3D细胞培养变得更加容易、高效和经济。能广泛应用于再生医学、精准医疗、疾病建模、发育生物学、毒物学、宿主-微生物组相互作用、药物发现和基因编辑等多个领域。
| 型号 | H389600P-6 孔 | H389600P-单人 |
| 材料 | 聚苯乙烯 | 聚苯乙烯 |
| 特征 | 大规模培养, 经济实惠,易于移液, 疏水性 | 大众培养, 经济实惠,易于移液, 疏水性 |
| 井数量 | 每个 2,334 | 389 个 |
| 井径 | 600 微米 | 600 微米 |
| 单元格数量 | ≥ 1.2 x 106 | ≥ 1.2 x 106 |
| 细胞接种培养基的体积 | 1 毫升 | 1 毫升 |
| 细胞培养基体积 | 3 ~ 8 毫升 | 3 毫升 |
| 包装 | 3 包/箱 | 20 个 EA/CS,40 个 EA/CS |
● StemFIT 3D®
StemFIT 3D®是一款创新性的三维细胞培养板,带有凹形微孔的微孔板,其核心原理在于利用这些微孔将孔内的细胞浓缩,进而培养细胞聚集体。使细胞能够在三维空间内相互作用,更好地模拟了体内细胞的生长环境。StemFIT 3D®在三个维度上形成细胞聚集体,允许细胞向各个方向生长并与周围环境相互作用,通过扩散和传递为细胞提供营养、氧气和药物,从而提供更接近生物体真实情况的仿生环境。
| 型号 | 井型 | 井数 | 井径 | 细胞数量 | 播种培养基体积 | 总培养基体积 |
| H1613200 | Hexagon | 1613 | 200 μm | ≥ 6.0 x 105 | 500 μl | 1 ml |
| H853400 | Hexagon | 853 | 400 μm | ≥ 1.2 x 106 | 1 ml | 1.5 ml |
| H389600L/H389600H | Hexagon | 389 | 600 μm | ≥ 1.2 x 106 | 1 ml | H389600L-1.3 ml;H389600H-1.7 ml |
| H449800 | Hexagon | 449 | 800 μm | ≥ 2.4 x 106 | 1 ml | 4 ml |
| H2951000 | Hexagon | 295 | 1000 μm | ≥ 2.4 x 106 | 2 ml | 4 ml |
| C100600 | Circle | 100 | 600 μm | ≥ 6.0 x 105 | 2 ml | 700 μl |
| C163000 | Circle | 16 | 3,000 μm | 2.5 x 105 / well | 20 μl / well | 5 ml |
| C253000 | Circle | 25 | 3,000 μm | 2.5 x 105 / well | 20 μl / well | 3 ml |
● NanoFIT 3D®系列
NanoFIT 3D®系列细胞培养板通过实现线或柱结构的均匀纳米图案来提供仿生界面。这种独特的纳米拓扑结构能够模拟细胞外环境,允许科研人员通过诱导细胞调整其形态和排列,从而更精准地控制和分析特定细胞的反应。它有可能基于纳米图案最大限度地维持和分化细胞,在体内提供类似于ECM(细胞外基质)的环境,使细胞的形态和功能更接近体内真实状态。能维持细胞干性与分化;调节特定细胞靶向;多样化培养形式并且拥有专利技术保障。
| Type | Pattern | Size | Cat. No. |
| Sheet (Polydimethylsiloxane) | Line | 250 nm | N-Line250S |
| Sheet (Polydimethylsiloxane) | Line | 400 nm | N-Line400S |
| Sheet (Polydimethylsiloxane) | Post | 250 nm | N-Post250S |
| Sheet (Polydimethylsiloxane) | Post | 400 nm | N-Post400S |
| Sheet (Polydimethylsiloxane) | Flat | 250 nm | N-Flat250S |
| Sheet (Polydimethylsiloxane) | Flat | 400 nm | N-Flat400S |
| Dish (Polystyrene) | Line | 400 nm | N-Line400P |
● 微珠芯片
微珠芯片是一种专为大规模生产微型珠子而设计的微流控装置。它采用先进的材料和工艺制造,旨在利用胶原蛋白、PEGDA、PLGA等多种水凝胶材料,实现高效、精准的大规模微粒生产。具有卓越的耐化学性;精密的珠子生产能力;材料坚固耐用且可重用。
● PDMS膜
PDMS膜,即聚二甲基硅氧烷膜,作为应用最为广泛的硅基有机聚合物之一,、PDMS膜具有柔软弹性,能够轻松实现大幅度的拉伸变形,且在拉伸过程中仍能保持较好的物理性能和稳定性;具备超薄膜的结构特点,厚度可以做到极薄,在保证基本功能的前提下,最大程度地减少材料的使用和空间的占用;拥有良好的透气性,它允许气体分子自由通过,在生物相容性应用中,能为细胞提供适宜的气体交换环境,促进细胞的生长和代谢;在微流体装置等应用里,也能保证气体的顺畅流通,维持系统的稳定运行;拥有优异的光学透明性,几乎不会对光线的传播产生干扰;对生物组织无毒无害,不会引发明显的免疫反应,可安全地应用于生物医学领域。
<| Material | Diameter | Thickness |
| PDMS | 50 mm / 1.97 inch | 10 μm |
| PDMS | 50 mm / 1.97 inch | 30 μm |
| PDMS | 50 mm / 1.97 inch | 50 μm |
● PDMS定位
PDMS(聚二甲基硅氧烷)作为一种硅基弹性体,拥有高光学透明度,能让研究人员清晰地观察芯片内发生的微观反应和现象;化学稳定性极佳,可在各种化学环境下保持性能稳定;出色的变形性使其能够适应不同的实验需求和操作条件;优异的生物相容性则为生物样本的研究提供了安全可靠的环境。PDMS片上实验室采用了世界领先的PDMS LOC(Lab - on - a - Chip)技术。这项技术实现了在微米尺度上构建具有卓越成型性的纳米·微结构,将复杂的实验室功能集成到一个小小的芯片之上。
● SU-8微型模具
SU-8微型模具是一种感光聚合物模具,专门用于芯片实验室的微图案铸造。它采用环氧树脂基负光刻胶SU-8作为主要材料,通过精密的光刻工艺在晶圆上制造出微图案。相较于其他模具材料,SU-8微型模具的生产速度更快。该模具的高度可高达1,000μm,能够满足制造具有较大高度微结构的需求。这种模具在微流控芯片、生物传感器、微机电系统(MEMS)等领域的生产制造中发挥着重要作用。
| 通道高度 | 晶圆尺寸 | 层 |
| 100 μm 以下 | 4英寸 | 1层 |
| 100 μm 以下 | 6英寸 | 1层 |
| 110 - 200 微米 | 4英寸 | 1层 |
| 110 - 200 微米 | 6英寸 | 1层 |
| 210 - 300 微米 | 4英寸 | 2 层 |
| 310 - 500 微米 | 4英寸 | 超过 2 层 |
| 510 - 800 微米 | 4英寸 | 超过 3 层 |
● 晶圆厂工艺
在半导体产业飞速发展的今天,高效、精准且可靠的制造服务至关重要。MicroFIT凭借其专业的技术和丰富的经验,提供一站式的半导体制造服务,采用分布式外包流程,为客户解决各种制造难题。包括以下服务:
● 光刻:将精心设计的图案精准转移到晶圆上,这是半导体制造的关键起始步骤,为后续的工艺奠定基础,确保图案的高精度和准确性。
● 镀膜:通过各种工艺使金属、聚合物等材料以薄膜形式均匀沉积在硅衬底上,为芯片提供必要的功能层和保护层,增强芯片的性能和稳定性。
● 蚀刻:精确去除必要电路图案外的其余部分,可选择干蚀刻或湿蚀刻方法,以实现对材料的精细加工,塑造出所需的微纳结构。
● 粘接:在半导体制造中,用于将芯片与基板牢固粘合;在微流控器件制造里,用于通道形成后的处理,确保器件各部分之间的可靠连接和密封性。
● 切割:把在半导体晶片加工中制造的器件在图案形成后分离成一定的尺寸,为后续的封装和测试等步骤做准备。
● CMP(化学机械抛光):通过化学和物理过程的结合,对晶圆或玻璃基板进行抛光压平,使表面达到极高的平整度,满足半导体器件制造的严格要求。
" data-original="http://applied.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理MicroFIT品牌全系列产品"> 艾美捷科技代理MicroFIT品牌全系列产品
PANAGENE公司成立于2006年,以独有的肽核酸技术,为全世界范围内的客户提供高纯度的肽核酸产品。PNA(peptide nucleic acids,PNA)肽核酸技术,是90年代丹麦科学家发明的一类以多肽骨架取代糖磷酸主链的DNA类似物,即以中性的肽链酰胺2-氨基乙基甘氨酸键取代了DNA中的戊糖磷酸二酯键骨架,其余的与DNA相同,PNA可以通过Watson-Crick碱基配对的形式识别并结合DNA或RNA序列,形成稳定的双螺旋结构。
PANAGENE have been supplying Peptide Nucleic Acid (PNA) worldwide and exclusively since 2006 based on our unique invention of efficient synthesis of PNA with high purity, and nowadays we are possessing the best knowledge on PNA and the largest number of patents on the PNA and its applications in the world.
PANAGENE的主要产品包括:
Custom PNA synthesis
Gamma PNA
PNA FISH probe
PNAs™ miRNA inhibitor
Globin Reduction PNA
Fmoc PNA monomer
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:17754422825
传真:18771997407
邮箱:sales@amyjet.com
0.3491